logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. AbbVie Inc.

    AbbVie Inc. drugs

    FiltersReset Filters
    32 results

    • creon

      (Pancrelipase)
      AbbVie Inc.
      Usage: CREON® is indicated for treating exocrine pancreatic insufficiency in both adult and pediatric patients.

    • depakote

      (Divalproex Sodium)
      AbbVie Inc.
      Usage: Depakote ER is indicated for treating acute manic or mixed episodes of bipolar disorder, complex partial seizures, simple and complex absence seizures, and for migraine prophylaxis. It is not effective for acute migraine treatment. Considerations regarding pregnancy and potential risks are crucial for women of childbearing potential.

    • depakote

      (Divalproex Sodium)
      AbbVie Inc.
      Usage: Depakote (divalproex sodium) is indicated for treating manic episodes in bipolar disorder, complex partial seizures, simple and complex absence seizures, and for migraine prophylaxis. Its long-term efficacy in treating mania is not established, and it should be avoided in women who are pregnant or may become pregnant.

    • depakote sprinkles - divalproex sodium capsule

      (Divalproex Sodium)
      Abbvie Inc.

    • duopa

      (Carbidopa and Levodopa)
      AbbVie Inc.
      Usage: DUOPA® is indicated for treating motor fluctuations in patients with advanced Parkinson’s disease.

    • emblaveo - aztreonam and avibactam powder, for solution

      (Aztreonam And Avibactam)
      Abbvie Inc.

    • emrelis

      (Telisotuzumab Vedotin)
      AbbVie Inc.
      Usage: EMRELIS is indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression (≥50% of tumor cells). It is for those who have previously received systemic therapy and is approved under accelerated conditions based on overall response rate.

    • gengraf

      (Cyclosporine)
      AbbVie Inc.
      Usage: Gengraf® (cyclosporine oral solution, USP [MODIFIED]) is indicated for the prevention of organ rejection in kidney, liver, and heart transplants, as well as for treating severe active rheumatoid arthritis unresponsive to methotrexate and severe plaque psoriasis in adults who have failed prior systemic therapies.

    • gengraf - cyclosporine capsule

      (Cyclosporine)
      Abbvie Inc.

    • humira - adalimumab

      (Adalimumab)
      Abbvie Inc.